Peptides
Research-use compounds, mechanisms, and what the data actually supports.
KPV for Inflammation and Gut Health: Why It May Be a More Targeted Research Tool Than BPC-157
KPV and BPC-157 both show up in gut and inflammation research, but they work through genuinely different mechanisms — and KPV's lack of angiogenic activity may make it the more precise tool for inflammation-specific research questions.
GHK-Cu: How This Copper Peptide Works, and the Surprising Range of Things It Does
GHK-Cu started as a curiosity found in human blood plasma and turned into one of the most broadly-studied peptides in skin, wound, and tissue research. Here's the mechanism, and the real range of documented effects.
Melanotan I vs. Melanotan II: Same Origins, Very Different Safety Profiles
Both trace back to the same 1980s research program, but one became an FDA-approved orphan drug and the other stayed an unregulated tanning agent with a genuinely concerning real-world adverse event record. Here's how they actually differ.
KLOW: What's Actually in the Blend, and What the Research on Each Component Shows
KLOW combines four peptides into one vial for a reason — but the research behind each component is stronger than the research behind combining them. Here's what's actually known.
RUO vs. Clinical Use: Understanding the Peptide Research Landscape
Research-use-only compounds occupy a specific, legal, and often misunderstood space in the peptide world. Here's what the label actually means — and what it doesn't.
Tirzepatide vs. Semaglutide: What the Head-to-Head Trials Show
For years, tirzepatide vs. semaglutide was argued from separate trials in different populations. SURMOUNT-5 finally put them head-to-head in the same study. Here's what it actually found.
Retatrutide: The Next GLP-1? What We Know So Far
Retatrutide has moved from Phase 2 buzz to real Phase 3 data in the last few months. Here's what the actual trial results show, and how they stack up against tirzepatide and semaglutide.
What Is BPC-157? A Look at the Current Research
BPC-157 has over a hundred animal studies behind it and a passionate following online. Here's an honest look at what the animal data shows, how thin the human evidence actually is, and where the regulatory story stands right now.